The researchers noted the effects measured are relevant to Fortigel, the specific BCP used in the study, and cannot be readily applicable to other collagen products
In a recent study from the University of Freiburg, Zdzieblik et al. investigated the benefits of Fortigel, specific bioactive collagen peptides from Gelita, designed to regenerate cartilage, maintain joint mobility, and minimise joint discomfort.
The study involved 180 physically active young men and women, reporting knee joint discomfort with physical activity, who supplemented with 5 g of Fortigel or a maltodextrin placebo for 12 weeks.
Supplementation with Fortigel resulted in statistically significant reduction in “pain during activity” compared with the placebo, as assessed by both the study participants and the physician. According to the authors of the study, this “may help to prevent the clinical manifestation of chronic degenerative joint diseases”.
These results confirm the previous findings from the researchers in 2017, when they observed a significant reduction in activity-related joint discomfort from the use of Fortigel compared with placebo, in a RCT involving 139 active men and women.
Dr Stephan Hausmanns, Gelita’s VP for Health & Nutrition said: “Fortigel is the most clinically-studied bioactive collagen peptides, for 30 years. Over 20 studies, involving more than 2,500 participants, contributed to develop Fortigel and prove the product’s positive effects to joint health”, he explains. “So far, no other collagen peptide solution on the market has been able to offer an alternative to Fortigel, backed by science”, concludes Stephan.